Paula Alves and Manuel Carrondo opinion on Biotechnology R&D in Portugal

Paula Alves, CEO of iBET, and Manuel Carrondo, Vice-President of iBET, shared expert insights on the current state of the art and future trends of Biotechnology R&D in Portugal in an opinion article for Jornal Económico.

Selected highlights:

• The portfolio of new biopharmaceuticals in development and clinical trials is growing.
• The development of innovative medicines requires multidisciplinarity and combining several technological competences.
• Over the last 10 years, Portugal has seen a steady increase in the number of biotechnology-based companies attracting foreign investment.
• iBET invests in research and innovative technologies putting its skills at the service of the economy and creating wealth and qualified jobs.
• With the ambition to foster international partnerships and keep attracting talent, iBET is committed to prepare the next generations of scientists, technologists and engineers in the development of innovative products.